The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment

A short guide to histone deacetylases including recent progress on class II enzymes

(2020) Suk-Youl Park et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo

(2020) Salome Paillas et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Searching for Potential HDAC2 inhibitors: Structure Activity Relationship Studies on Indole-based Hydroxamic Acids as Anticancer Agent

(2020) Ekta Shirbhate et al.   Letters in Drug Design & Discovery

Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells

(2020) Asmita Sharda et al.   Clinical Epigenetics

HDAC6 regulates DNA damage response via deacetylating MLH1

(2019) Mu Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells

(2019) Simone Moertl et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway

(2018) Wei Yang et al.   CANCER LETTERS

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

(2018) Amila Suraweera et al.   Frontiers in Oncology

Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone deacetylase sodium butyrate and valproic acid

(2018) Marina Perona et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents

(2018) Loredana Cappellacci et al.   CURRENT MEDICINAL CHEMISTRY

The possible prognostic role of histone deacetylase and transforming growth factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study

(2017) Roberta Sferra et al.   EUROPEAN JOURNAL OF HISTOCHEMISTRY

Panobinostat for the management of multiple myeloma

(2017) Dharshan Sivaraj et al.   Future Oncology

Histone Deacetylase Inhibitors as Anticancer Drugs

(2017) Tomas Eckschlager et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial

(2017) Clara Y.H. Choi et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity

(2017) Blaz Groselj et al.   MOLECULAR CANCER THERAPEUTICS

Deacetylase inhibitors: an advance in myeloma therapy?

(2017) Jacob P. Laubach et al.   Expert Review of Hematology

Pharmacophore Based 3D-QSAR, Virtual Screening and Docking Studies on Novel Series of HDAC Inhibitors with Thiophen Linker as Anticancer Agents

(2016) Preeti Patel et al.   COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING

Histone deacetylases: structural determinants of inhibitor selectivity

(2015) Carmina Micelli et al.   DRUG DISCOVERY TODAY

The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: A review

(2015) F. Vahid et al.   GENE

Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators

(2015) Peng Zhan et al.   JOURNAL OF MEDICINAL CHEMISTRY

The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells

(2015) Abdel Nasser Hosein et al.   JOURNAL OF NEURO-ONCOLOGY

A Structural Insight into Hydroxamic Acid Based Histone Deacetylase Inhibitors for the Presence of Anticancer Activity

(2014) H. Rajak et al.   CURRENT MEDICINAL CHEMISTRY

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair

(2013) B Groselj et al.   BRITISH JOURNAL OF CANCER

Investigating the Selectivity of Metalloenzyme Inhibitors

(2013) Joshua A. Day et al.   JOURNAL OF MEDICINAL CHEMISTRY

Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo

(2013) Wenwen Chien et al.   MOLECULAR CARCINOGENESIS

Small Molecule Inhibitors of Zinc-dependent Histone Deacetylases

(2013) Florence F. Wagner et al.   Neurotherapeutics

HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression

(2013) Qinghua Dong et al.   TOXICOLOGY LETTERS

Histone deacetylase inhibitors: a patent review (2009 – 2011)

(2012) Vincenzo Carafa et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Structure of HDAC3 bound to co-repressor and inositol tetraphosphate

(2012) Peter J. Watson et al.   NATURE

Epigenetic protein families: a new frontier for drug discovery

(2012) Cheryl H. Arrowsmith et al.   NATURE REVIEWS DRUG DISCOVERY

Novel and Selective Inhibitors of Histone Deacetylase

(2012) Gerard Rosse   ACS Medicinal Chemistry Letters

Erratum

(2011)   Expert Review of Anticancer Therapy

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

(2011) K Ted Thurn et al.   Future Oncology

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors

(2011) Claudia P. Miller et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic

(2011) Jacob E. Shabason et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance

(2011) Robert W. Robey et al.   MOLECULAR PHARMACEUTICS

Induction of superficial cortical layer neurons from mouse embryonic stem cells by valproic acid

(2011) Berry Juliandi et al.   NEUROSCIENCE RESEARCH

Sensitization to γ-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells

(2010) Feng Zhang et al.   CANCER BIOLOGY & THERAPY

Three-Dimensional Cell Growth Confers Radioresistance by Chromatin Density Modification

(2010) K. Storch et al.   CANCER RESEARCH

Enhancement of Radiation Response in Osteosarcoma and Rhabomyosarcoma Cell Lines by Histone Deacetylase Inhibition

(2010) Claudia Blattmann et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study

(2010) Anne Hansen Ree et al.   LANCET ONCOLOGY

HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer Cells

(2009) Xufeng Chen et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Successful Treatment of Anaplastic Thyroid Carcinoma with a Combination of Oral Valproic Acid, Chemotherapy, Radiation and Surgery

(2009) Hitoshi NOGUCHI et al.   ENDOCRINE JOURNAL

Radiosensitization by SAHA in Experimental Colorectal Carcinoma Models—In Vivo Effects and Relevance of Histone Acetylation Status

(2009) Sigurd Folkvord et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts

(2009) A. Baschnagel et al.   MOLECULAR CANCER THERAPEUTICS

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?

(2008) L Nolan et al.   BRITISH JOURNAL OF CANCER